Case Report: Guillain-Barré syndrome temporally associated with levofloxacin exposure and improvement following efgartigimod treatment
Abstract
Levofloxacin, the L-isomer of the racemic fluoroquinolone ofloxacin, is a broad-spectrum antibiotic with broad clinical applications in both prophylactic and therapeutic indications. However, it has been associated with various adverse reactions, including Guillain-Barré syndrome (GBS). GBS is an immune-mediated peripheral neuropathy that typically presents with acute-onset symmetrical flaccid paralysis. Here, we report a case of GBS temporally associated with levofloxacin exposure that improved after initiation of efgartigimod, following limited response to plasma exchange, methylprednisolone, and intravenous immunoglobulin. To our knowledge, there are no previously published cases of GBS associated with levofloxacin exposure treated with efgartigimod therapy. This case suggests that efgartigimod may represent a promising treatment option for GBS temporally associated with levofloxacin exposure. However, this single case cannot establish efficacy, and delayed responses to prior therapies or spontaneous recovery remain possible alternative explanations. Further studies with larger cohorts are needed to clarify the mechanisms underlying this therapy.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.